Suppressor and oncogenic roles of transforming growth factor-β and its signaling pathways in tumorigenesis

doi:10.1016/S0065-230X(01)83001-3

Advances in Cancer Research

Volume 83, 2001, Pages 1-54

https://doi.org/10.1016/S0065-230X(01)83001-3 Get rights and content

Abstract

Transforming growth factor-β (TGF-β) has been implicated in oncogenesis since the time of its discovery almost 20 years ago. The complex, multifunctional activities of TGF-β endow it with both tumor suppressor and tumor promoting activities, depending on the stage of carcinogenesis and the responsivity of the tumor cell. Dysregulation or alteration of TGF-β signaling in tumorigenesis can occur at many different levels, including activation of the ligand, mutation or transcriptional suppression of the receptors, or alteration of downstream signal transduction pathways resulting from mutation or changes in expression patterns of signaling intermediates or from changes in expression of other proteins which modulate signaling. New insights into signaling from the TGF-β receptors, including the identification of Smad signaling pathways and their interaction with mitogen-activated protein (MAP) kinase pathways, are providing an understanding of the changes involved in the change from tumor suppressor to tumor promoting activities of TGF-β. It is now appreciated that loss of sensitivity to inhibition of growth by TGF-β by most tumor cells is not synonymous with complete loss of TGF-β signaling but rather suggests that tumor cells gain advantage by selective inactivation of the tumor suppressor activities of TGF-β with retention of its tumor promoting activities, especially those dependent on cross talk with MAP kinase pathways and AP-1.

References (350)

P.J. Adam et al.
J. Biol. Chem.
(2000)
M. Afrakhte et al.
A. Agrotis et al.
FEBS Lett.
(2000)
D. Albo et al.
J. Gastrointest. Surg.
(1999)
T. Arai et al.
Cancer Lett.
(1998)
A. Atfi et al.
J. Biol. Chem.
(1997)
A.V. Bakin et al.
J. Biol. Chem.
(2000)
N.P. Barbara et al.
J. Biol. Chem.
(1999)
M.C. Birchenall-Roberts et al.
J. Biol. Chem.
(1991)
S.W. Blain et al.
J. Biol. Chem.
(2000)

M.G. Alexandrow et al.

C. Amendt et al.

Oncogene

(1998)

S.R. Amoroso et al.

P.A. Andreasen et al.

Cell. Mol. Life Sci.

(2000)

E.A. Ariazi et al.

Cancer Res.

(1999)

J.P. Arnoletti et al.

Cancer

(1995)

B.A. Arrick et al.

J. Cell Biol.

(1992)

C.L. Arteaga et al.

J. Clin. Invest.

(1993)

C.L. Arteaga et al.

J. Cell Biochem. Suppl.

(1993)

E.R. Barrack

Prostate

(1997)

S. Bevan et al.

Gut

(1999)

S. Birkey-Reffey et al.

J. Biol. Chem.

(2001)

M. Bitzer et al.

Genes Dev.

(2000)

G.C. Blobe et al.

N. Engl. J. Med.

(2000)

B. Bodey et al.

Anticancer Res.

(1998)

W.A. Border et al.

N. Engl. J. Med.

(1994)

J.L. Bos

Cancer Res.

(1989)

E.P. Bottinger et al.

Cancer Res.

(1997)

B.F. Boyce et al.

Endocrinol. Relat. Cancer

(1999)

G. Brodin et al.

Cancer Res.

(1999)

Cited by (92)

Stimulation of ATF3 interaction with Smad4 via TGF-β1 for matrix metalloproteinase 13 gene activation in human breast cancer cells
2019, International Journal of Biological Macromolecules
We previously reported that transforming growth factor-β1 (TGF-β1) stimulated the sustained and prolonged expression of activating transcription factor 3 (ATF3) in highly metastatic and invasive human breast cancer cells (MDA-MB231), in contrast to normal human mammary epithelial cells. However, the mechanism behind the stability of ATF3 expression is not yet known. Based on an in silico approach with co-immunoprecipitation and mass spectrometric analyses, we identified a number of proteins, including Smad4, that interacted with ATF3 after TGF-β1 treatment in MDA-MB231 cells. The knockdown of Smad4 using the siRNA technique resulted in a significant loss of ATF3 expression in these cells. Chromatin immunoprecipitation was then used to identify the formation of an ATF3 and Smad4 complex at the matrix metalloproteinase 13 (MMP13) promoter upon TGF-β1-treatment, and the knockdown of Smad4 decreased MMP13 promoter activity in MDA-MB231 cells. Our findings indicate that Smad4 is a pre-requisite for providing stability to ATF3 via TGF-β1 in human breast cancer cells. The targeting of Smad4 may thus provide the sustainable loss of ATF3 expression that is needed to control breast cancer progression.
Mechanisms of action of acetaldehyde in the up-regulation of the human α2(I) collagen gene in hepatic stellate cells: Key roles of Ski, SMAD3, SMAD4, and SMAD7
2014, American Journal of Pathology
Alcohol-induced liver fibrosis and eventually cirrhosis is a leading cause of death. Acetaldehyde, the first metabolite of ethanol, up-regulates expression of the human α2(I) collagen gene (COL1A2). Early acetaldehyde-mediated effects involve phosphorylation and nuclear translocation of SMAD3/4–containing complexes that bind to COL1A2 promoter to induce fibrogenesis. We used human and mouse hepatic stellate cells to elucidate the mechanisms whereby acetaldehyde up-regulates COL1A2 by modulating the role of Ski and the expression of SMADs 3, 4, and 7. Acetaldehyde induced up-regulation of COL1A2 by 3.5-fold, with concomitant increases in the mRNA (threefold) and protein (4.2- and 3.5-fold) levels of SMAD3 and SMAD4, respectively. It also caused a 60% decrease in SMAD7 expression. Ski, a member of the Ski/Sno oncogene family, is colocalized in the nucleus with SMAD4. Acetaldehyde induces translocation of Ski and SMAD4 to the cytoplasm, where Ski undergoes proteasomal degradation, as confirmed by the ability of the proteasomal inhibitor lactacystin to blunt up-regulation of acetaldehyde-dependent COL1A2, but not of the nonspecific fibronectin gene (FN1). We conclude that acetaldehyde up-regulates COL1A2 by enhancing expression of the transactivators SMAD3 and SMAD4 while inhibiting the repressor SMAD7, along with promoting Ski translocation from the nucleus to cytoplasm. We speculate that drugs that prevent proteasomal degradation of repressors targeting COL1A2 may have antifibrogenic properties.
RB1CC1 protein positively regulates transforming growth factor-β signaling through the modulation of Arkadia E3 ubiquitin ligase activity
2011, Journal of Biological Chemistry
Citation Excerpt :
The TGF-β-Smad pathway is also thought to have tumor suppressor functions during the early stages of tumorigenesis as TGF-β exhibits potent antiproliferative activity in a wide variety of cells. Additionally, mutations of signaling components downstream of TGF-β have been identified in tumor tissues (66). In this study we demonstrated that RB1CC1 is a positive regulator of TGF-β signaling under physiological conditions; knockdown of RB1CC1 attenuated expression of target genes as well as cytostasis induced by TGF-β.
Transforming growth factor-β (TGF-β) signaling is controlled by a variety of regulators, of which Smad7, c-Ski, and SnoN play a pivotal role in its negative regulation. Arkadia is a RING-type E3 ubiquitin ligase that targets these negative regulators for degradation to enhance TGF-β signaling. In the present study we identified a candidate human tumor suppressor gene product RB1CC1/FIP200 as a novel positive regulator of TGF-β signaling that functions as a substrate-selective cofactor of Arkadia. Overexpression of RB1CC1 enhanced TGF-β signaling, and knockdown of endogenous RB1CC1 attenuated TGF-β-induced expression of target genes as well as TGF-β-induced cytostasis. RB1CC1 down-regulated the protein levels of c-Ski but not SnoN by enhancing the activity of Arkadia E3 ligase toward c-Ski. Substrate selectivity is primarily attributable to the physical interaction of RB1CC1 with substrates, suggesting its role as a scaffold protein. RB1CC1 thus appears to play a unique role as a modulator of TGF-β signaling by restricting substrate specificity of Arkadia.
Homeostatic role of transforming growth factor-β in the oral cavity and esophagus of mice and its expression by mast cells in these tissues
2009, American Journal of Pathology
Transforming growth factor-β (TGF-β) is a pleiotropic growth factor; its overexpression has been implicated in many diseases, making it a desirable target for therapeutic neutralization. In initial safety studies, mice were chronically treated (three times per week) with high doses (50 mg/kg) of a murine, pan-neutralizing, anti-TGF-β antibody. Nine weeks after the initiation of treatment, a subset of mice exhibited weight loss that was concurrent with decreased food intake. Histopathology revealed a unique, nonneoplastic cystic epithelial hyperplasia and tongue inflammation, as well as dental dysplasia and epithelial hyperplasia and inflammation of both the gingiva and esophagus. In an effort to determine the cause of this site-specific pathology, we examined TGF-β expression in these tissues and saliva under normal conditions. By immunostaining, we found higher expression levels of active TGF-β1 and TGF-β3 in normal tongue and esophageal submucosa compared with gut mucosal tissues, as well as detectable TGF-β1 in normal saliva by Western blot analysis. Interestingly, mast cells within the tongue, esophagus, and skin co-localized predominantly with the TGF-β1 expressed in these tissues. Our findings demonstrate a novel and restricted pathology in oral and esophageal tissues of mice chronically treated with anti-TGF-β that is associated with basal TGF-β expression in saliva and by mast cells within these tissues. These studies illustrate a previously unappreciated biological role of TGF-β in maintaining homeostasis within both oral and esophageal tissues.
Transforming growth factor-β1 up-regulates connexin43 expression in osteocytes via canonical Smad-dependent signaling pathway
2018, Bioscience Reports
Down-regulation of HOXB5 inhibits TGF-β-induced migration and invasion in hepatocellular carcinoma cells via inactivation of the PI3K/Akt pathway
2018, RSC Advances

View all citing articles on Scopus

View full text

Suppressor and oncogenic roles of transforming growth factor-β and its signaling pathways in tumorigenesis

Abstract

J. Biol. Chem.

FEBS Lett.

J. Gastrointest. Surg.

Cancer Lett.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

J. Biol. Chem.

Cell

Cell

J. Biol. Chem.

Biochim. Biophys. Acta

Cell

J. Biol. Chem.

Cell

Cell

Blood

Int. J. Biochem. Cell Biol.

J. Biol. Chem.

Cytokine Growth Factor Rev.

J. Pathol.

Br. J. Cancer

J. Cell. Biochem.

Oncogene

Cell. Mol. Life Sci.

Cancer Res.

Cancer

J. Cell Biol.

J. Clin. Invest.

J. Cell Biochem. Suppl.

Prostate

Gut

J. Biol. Chem.

Genes Dev.

N. Engl. J. Med.

Anticancer Res.

N. Engl. J. Med.

Cancer Res.

Cancer Res.

Endocrinol. Relat. Cancer

Cancer Res.